Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region

Basit Öğe Kaydı
dc.contributor.authorOrmeci, Necati
dc.contributor.authorGulsen, Murat Taner
dc.contributor.authorSezgin, Orhan
dc.contributor.authorAghayeva, Sevda
dc.contributor.authorDemir, Mehmet
dc.contributor.authorKoksal, Iftihar
dc.contributor.authorGuner, Rahmet
dc.date.accessioned2024-09-18T20:26:41Z
dc.date.available2024-09-18T20:26:41Z
dc.date.issued2020
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.descriptionAPASL Single Topic Congress -- SEP 27-29, 2018 -- Istanbul, TURKEYen_US
dc.description.abstractBackground/Aims: Hepatitis C virus (HCV) infection is a common disease that causes liver cirrhosis, hepatocellular carcinoma, and extra hepatic manifestations with high mortality and morbidity rates. This study aimed to present real-life experiences and results of treatment of HCV infection with direct-acting antiviral agents (DAAs) from the Euro-Asian region, including Turkey and Azerbaijan. Materials and Methods: A total of 1224 patients with chronic HCV infection were treated with DAAs in accordance with the international guidelines for the management of HCV infection. The mean age was 58.74 +/- 14.75 years, with 713 (58.25%) females. The genotypes of the patients were as follows: genotype 1b, 83.36% (n=1024); genotype 1a, 8.08% (n=99); genotype 2, 2.85% (n=35); genotype 3, 3.34% (n=41); genotype 4, 1.71% (n=21); and combined genotypes, 0.32% (n=4). Approximately 808 patients were treated with sofosbuvir-based DAAs with or without Ribavirin for 12 or 24 weeks, whereas 416 patients were treated with the Paritaprevir, Ombitasvir, Ritonavir.Dasabuvir (PROD) regimen with or without Ribavirin for 12 weeks or 24 weeks. Results: At the end of follow-up examinations, 1183 patients (97.93%) had sustained virological response (SVR), 17 (1.40%) died of reasons unrelated to the treatment regimen, 12 had recurrence after treatment, and 129 (10.67%) had adverse events like anemia, itching, and weakness. Conclusion: In this large cohort of HCV-infected patients, treatment with DAAs yielded a high overall SVR rate of 97.93%. DAAs were safe and well-tolerated. Thus, the elimination of HCV infection is no longer a dream worldwide.en_US
dc.description.sponsorshipAPASLen_US
dc.identifier.doi10.5152/tjg.2020.19440
dc.identifier.endpage155en_US
dc.identifier.issn2148-5607
dc.identifier.issue2en_US
dc.identifier.pmid32141824en_US
dc.identifier.scopus2-s2.0-85081530760en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage148en_US
dc.identifier.trdizinid419939en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2020.19440
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/419939
dc.identifier.urihttps://hdl.handle.net/20.500.12483/10478
dc.identifier.volume31en_US
dc.identifier.wosWOS:000518828400010en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectHepatitis C virusen_US
dc.subjectdirect-acting antiviral agentsen_US
dc.subjecttreatmenten_US
dc.titleTreatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian regionen_US
dc.typeConference Objecten_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
784.91 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu